Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Mark Previti"'
Autor:
Baharak Bahmani, Hua Gong, Brian T. Luk, Kristofer J. Haushalter, Ethel DeTeresa, Mark Previti, Jiarong Zhou, Weiwei Gao, Jack D. Bui, Liangfang Zhang, Ronnie H. Fang, Jie Zhang
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
The immunostimulatory properties of TLR7/8 agonists, such as resiquimod, have been exploited for cancer immunotherapy. Here, the authors design platelet membrane-cloaked nanoparticles for selective intratumoral delivery of resiquimod, resulting in po
Externí odkaz:
https://doaj.org/article/70f51776b4444f01b293b1d2b1518bff
Autor:
Hua Gong, Weiwei Gao, Liangfang Zhang, Mark Previti, Ethel DeTeresa, Jie Zhang, Ronnie H. Fang, Brian T. Luk, Kristofer J. Haushalter, Jiarong Zhou, Baharak Bahmani, Jack D. Bui
Publikováno v:
Nature Communications
Nature communications, vol 12, iss 1
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Nature communications, vol 12, iss 1
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Intratumoral immunotherapy is an emerging modality for the treatment of solid tumors. Toll-like receptor (TLR) agonists have shown promise for eliciting immune responses, but systemic administration often results in the development of adverse side ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f0db4db29ccae02a9cdf386542bf5fd
http://europepmc.org/articles/PMC8012593
http://europepmc.org/articles/PMC8012593